Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Regeneron Pharmaceuticals (NasdaqNM:REGN)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Location
777 Old Saw Mill River Road
Tarrytown, NY 10591
Phone: (914) 347-7000
Fax: (914) 347-2113
Email: info@regpha.com
Employees (last reported count): 491
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Index Membership
 ·S&P 600 SmallCap
Ownership
·Insider and 5%+ Owners: 64%
·Over the last 6 months:
 · 6 insider sells; 1.53M shares
  (5.2% of insider shares)
·Institutional: 51% (144% of float)
(230 institutions)
·Net Inst. Buying: 1.08M shares (+4.58%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. Expanding from its initial focus on degenerative neurologic diseases, the Company has more recently broadened its product pipeline to include drug candidates for the treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, ischemia, and other diseases and disorders.
More from Market Guide: Expanded Business Description

Financial Summary
REGN is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for the treatment of serious medical conditions. For the six months ended 6/30/01, total revenues fell 52% to $12.1 million. Net loss before acct. change rose from $10.1 million to $27.9 million. Revenues reflect lower research payments on the Proctor and Gamble contract. Higher loss reflects staff additions, and increased preclinical and clinical research activities.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

P. Roy Vagelos, M.D., 71
Chairman
--  --  
Leonard Schleifer, M.D., Ph.D., 48
Pres, CEO, Director
$596K--  
Murray Goldberg, 56
CFO, Sr. VP-Fin. and Admin.,Treasurer, Assistant Secre
260K$863K
George Yancopoulos, M.D., Ph.D., 41
Exec. VP, CSO and Pres, Regeneron Research Laboratories,
374K--  
Randall Rupp, Ph.D., 53
Sr. VP, Manufacturing and Process Sciences
229K101K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:REGNAs of 31-Aug-2001
Price and Volume
52-Week Low
on 22-Nov-2000
$19.625
Recent Price$30.12 
52-Week High
on 19-Dec-2000
$41.688
Beta0.41 
Daily Volume (3-month avg)168.7K
Daily Volume (10-day avg)97.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-11.7%
52-Week Change
relative to S&P500
+18.4%
Share-Related Items
Market Capitalization$1.32B
Shares Outstanding43.7M
Float15.6M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$7.18 
Earnings (ttm)-$1.00 
Earnings (mrq)-$0.34 
Sales (ttm)$1.20 
Cash (mrq)$5.61 
Valuation Ratios
Price/Book (mrq)4.20 
Price/EarningsN/A 
Price/Sales (ttm)25.07 
Income Statements
Sales (ttm)$46.2M
EBITDA (ttm)-$42.7M
Income available to common (ttm)-$39.4M
Profitability
Profit Margin (ttm)-85.3%
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-15.03%
Return on Equity (ttm)-16.62%
Financial Strength
Current Ratio (mrq)19.56 
Debt/Equity (mrq)0.01 
Total Cash (mrq)$244.8M
Short Interest
As of 8-Aug-2001
Shares Short1.50M
Percent of Float9.6%
Shares Short
(Prior Month)
1.50M
Short Ratio10.09 
Daily Volume149.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   B = billions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.